{"id":317,"date":"2020-06-27T08:41:57","date_gmt":"2020-06-27T08:41:57","guid":{"rendered":"https:\/\/nclinnovations.org\/covid19monitor\/?p=317"},"modified":"2020-06-27T08:41:57","modified_gmt":"2020-06-27T08:41:57","slug":"26-june-2020-tocilizumab-85-9-vs-71-9-survival-among-tocilizumab-methylprednisolone-soc-patients-vs-soc","status":"publish","type":"post","link":"https:\/\/nclinnovations.org\/covid19monitor\/26-june-2020-tocilizumab-85-9-vs-71-9-survival-among-tocilizumab-methylprednisolone-soc-patients-vs-soc\/","title":{"rendered":"(26 June 2020) Tocilizumab- 85.9% vs. 71.9% survival among tocilizumab\/methylprednisolone\/SOC patients vs. SOC"},"content":{"rendered":"<div class=\"boldgrid-section\">\n<div class=\"container\">\n<div class=\"row\">\n<div class=\"col-md-12 col-xs-12 col-sm-12\">\n<p>Tocilizumab and steroid treatment in patients with COVID-19 pneumonia<\/p>\n<p>https:\/\/doi.org\/10.1101\/2020.06.22.20133413<\/p>\n<p class=\"\">This observational single-center study included patients with COVID-19 pneumonia who were not intubated and received either standard of care (SOC, controls) or SOC plus early (within 3 days from hospital admission) anti-inflammatory treatment. Overall, 196 adults were included in the analyses. They were mainly male (67.4%), with comorbidities (78.1%) and severe COVID-19 pneumonia (83.7%). Median age was 67.9 years (range, 30-100) and median PaO2\/FiO2 200 mmHg (IQR 133-289). Among them, 130 received early anti-inflammatory treatment with: tocilizumab (n=29, 22.3%), methylprednisolone (n=45, 34.6%), or both (n=56, 43.1%). The&nbsp;overall survival among tocilizumab\/methylprednisolone\/SOC patients vs. SOC was 85.9% (95%CI, 80.7-92.6) vs. 71.9% (95%CI, 46-73), HROW 0.41, 95%CI: 0.19-0.89, p=0.025. Early adjunctive treatment with tocilizumab, methylprednisolone or both may improve outcomes in non-intubated patients with COVID-19 pneumonia.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Tocilizumab and steroid treatment in patients with COVID-19 pneumonia https:\/\/doi.org\/10.1101\/2020.06.22.20133413 This observational single-center study included patients with COVID-19 pneumonia who were not intubated and received either standard of care (SOC, controls) or SOC plus early (within 3 days from hospital&hellip; <span class=\"read-more-span\"><a href=\"https:\/\/nclinnovations.org\/covid19monitor\/26-june-2020-tocilizumab-85-9-vs-71-9-survival-among-tocilizumab-methylprednisolone-soc-patients-vs-soc\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;(26 June 2020) Tocilizumab- 85.9% vs. 71.9% survival among tocilizumab\/methylprednisolone\/SOC patients vs. SOC&#8221;<\/span> <span class=\"genericon genericon-next\"><\/span><\/a><\/span><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"bgseo_title":"","bgseo_description":"","bgseo_robots_index":"index","bgseo_robots_follow":"follow"},"categories":[4,69,18],"tags":[53,27],"_links":{"self":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/317"}],"collection":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/comments?post=317"}],"version-history":[{"count":1,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/317\/revisions"}],"predecessor-version":[{"id":318,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/317\/revisions\/318"}],"wp:attachment":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/media?parent=317"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/categories?post=317"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/tags?post=317"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}